Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 17 (5)

Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

Affiliations

Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

Chien-Yu Lin et al. Int J Environ Res Public Health.

Abstract

Renal calculi are common, with male predilection and androgen exposure potentially increasing the risk of renal calculi. Systemic effects of androgen deprivation therapy (ADT) have been observed but the influence of ADT on renal calculi in prostate cancer (PCa) patients is not fully understood. We conducted this population-based study to evaluate the impact of ADT on the subsequent risk of renal calculi. We used the National Health Insurance Research Database of Taiwan to analyze the incidences of renal calculi in ADT patients and non-ADT patients from 2001 to 2013. In total, 3309 patients with PCa were selected. After matching with 1:1 propensity-score analysis, 758 ADT patients with 758 matched non-ADT controls were enrolled in the final analysis. Demographic characteristics were analyzed and Cox regression analysis for calculating the hazard ratios (HR) was performed for the subsequent risk of renal calculi. Finally, 186 (186/1516, 12.3%) patients with diagnosed renal calculi were detected. ADT patients had a lower risk of subsequent renal calculi with an adjusted HR of 0.38 (7% vs. 17.5%, 95% confidence interval (CI) 0.28-0.53; p < 0.001) in comparison with the non-ADT group. The Kaplan-Meier curve showed significant differences of cumulative incidences of renal calculi. In conclusion, ADT patients had approximately one-third lower risk of subsequent renal calculi. Further studies are warranted to evaluate the clinical significance.

Keywords: National Health Insurance Research Database; androgen deprivation therapy; prostate cancer; renal calculi; urolithiasis.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study flowchart of cohort selection. ADT: androgen deprivation therapy; NHIRD: National Health Insurance Research Database.
Figure 2
Figure 2
Kaplan–Meier curves according to androgen deprivation therapy use for the incidence of renal calculi in the propensity score–matched cohort. ADT, androgen deprivation therapy.

Similar articles

See all similar articles

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017;67:7–30. doi: 10.3322/caac.21387. - DOI - PubMed
    1. Di Zazzo E., Galasso G., Giovannelli P., Di Donato M., Di Santi A., Cernera G., Rossi V., Abbondanza C., Moncharmont B., Sinisi A.A., et al. Prostate cancer stem cells: The role of androgen and estrogen receptors. Oncotarget. 2015;7:193–208. doi: 10.18632/oncotarget.6220. - DOI - PMC - PubMed
    1. Aragon-Ching J.B., Williams K.M., Gulley J. Impact of androgen-deprivation therapy on the immune system: Implications for combination therapy of prostate cancer. Front. Biosci. 2007;12:4957–4971. doi: 10.2741/2441. - DOI - PubMed
    1. Kalina J.L., Neilson D.S., Comber A.P., Rauw J., Alexander A., Vergidis J., Lum J.J. Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers. 2017;9:13 doi: 10.3390/cancers9020013. - DOI - PMC - PubMed
    1. Liu J.-M., Lin C.-Y., Chuang H.-C., Hsu R.-J. No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: A 17-year population-based study. Ther. Clin. Risk Manag. 2018;14:1831–1837. doi: 10.2147/TCRM.S175244. - DOI - PMC - PubMed

Publication types

Feedback